$PULM
Pulmatrix, Inc.

2014 Q3 Form 10-Q Financial Statement

#000114420414050327 Filed on August 14, 2014

View on sec.gov

Income Statement

Concept 2014 Q3 2014 Q2 2013 Q2
Revenue $30.00K $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $1.086M $1.043M $302.0K
YoY Change 117.64% 245.36%
% of Gross Profit
Research & Development $1.929M $1.729M $175.0K
YoY Change 289.7% 888.0% 1650.0%
% of Gross Profit
Depreciation & Amortization $0.00 $0.00 $1.000K
YoY Change -100.0%
% of Gross Profit
Operating Expenses $2.624M $2.451M $477.0K
YoY Change 163.98% 413.84% 4670.0%
Operating Profit -$2.594M -$2.451M -$477.0K
YoY Change 160.97% 413.84%
Interest Expense $7.885M $5.613M
YoY Change
% of Operating Profit
Other Income/Expense, Net $5.000K $4.000K $0.00
YoY Change
Pretax Income -$1.710M -$1.720M -$480.0K
YoY Change 72.73% 258.33% 4700.0%
Income Tax $0.00 $0.00
% Of Pretax Income
Net Earnings -$11.13M -$6.941M -$477.0K
YoY Change 1020.12% 1355.14% 4670.0%
Net Earnings / Revenue -37113.33%
Basic Earnings Per Share
Diluted Earnings Per Share -$9.000M -$9.053M -$2.824M
COMMON SHARES
Basic Shares Outstanding 4.804M shares
Diluted Shares Outstanding

Balance Sheet

Concept 2014 Q3 2014 Q2 2013 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $12.88M $14.27M $50.00K
YoY Change 14211.11% 28440.0%
Cash & Equivalents $753.0K $1.506M $53.00K
Short-Term Investments
Other Short-Term Assets $20.00K $50.00K $100.0K
YoY Change -90.48% -50.0%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $13.17M $14.64M $160.0K
YoY Change 4289.67% 9052.5%
LONG-TERM ASSETS
Property, Plant & Equipment $105.0K $3.000K $0.00
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $550.0K
YoY Change
Total Long-Term Assets $105.0K $3.000K $550.0K
YoY Change -87.2% -99.45%
TOTAL ASSETS
Total Short-Term Assets $13.17M $14.64M $160.0K
Total Long-Term Assets $105.0K $3.000K $550.0K
Total Assets $13.27M $14.65M $710.0K
YoY Change 1085.18% 1962.96%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $310.0K
YoY Change
Accrued Expenses $570.0K $540.0K $40.00K
YoY Change 612.5% 1250.0%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $575.0K $550.0K $900.0K
YoY Change -56.77% -38.89%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities $0.00 $0.00 $0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $575.0K $550.0K $900.0K
Total Long-Term Liabilities $0.00 $0.00 $0.00
Total Liabilities $580.0K $550.0K $900.0K
YoY Change -56.39% -38.89%
SHAREHOLDERS EQUITY
Retained Earnings -$7.094M -$5.384M
YoY Change
Common Stock $480.00 $480.00
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $12.70M $14.10M -$190.0K
YoY Change
Total Liabilities & Shareholders Equity $13.27M $14.65M $710.0K
YoY Change 1085.18% 1962.96%

Cashflow Statement

Concept 2014 Q3 2014 Q2 2013 Q2
OPERATING ACTIVITIES
Net Income -$11.13M -$6.941M -$477.0K
YoY Change 1020.12% 1355.14% 4670.0%
Depreciation, Depletion And Amortization $0.00 $0.00 $1.000K
YoY Change -100.0%
Cash From Operating Activities -$1.280M -$1.640M -$330.0K
YoY Change 24.27% 396.97% 3200.0%
INVESTING ACTIVITIES
Capital Expenditures -$100.0K $1.000K $0.00
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities -$100.0K $0.00 $0.00
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -10.00K 340.0K 290.0K
YoY Change -100.94% 17.24% 2800.0%
NET CHANGE
Cash From Operating Activities -1.280M -1.640M -330.0K
Cash From Investing Activities -100.0K 0.000 0.000
Cash From Financing Activities -10.00K 340.0K 290.0K
Net Change In Cash -1.390M -1.300M -40.00K
YoY Change -4733.33% 3150.0%
FREE CASH FLOW
Cash From Operating Activities -$1.280M -$1.640M -$330.0K
Capital Expenditures -$100.0K $1.000K $0.00
Free Cash Flow -$1.180M -$1.641M -$330.0K
YoY Change 14.56% 397.27% 3200.0%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2014Q2 us-gaap Liabilities Current
LiabilitiesCurrent
550000 USD
CY2014Q2 us-gaap Use Of Estimates
UseOfEstimates
<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> <strong><i>Use of Estimates</i></strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent liabilities at the dates of the financial statements and the reported amounts of revenues and expenses during the reporting periods. Actual results could differ from these estimates. Significant estimates and assumptions include stock-based compensation, the valuation allowance related to the Company&#8217;s deferred tax assets and the expense allocations relating to the Company&#8217;s operations prior to its deconsolidation from Oculus Innovative Sciences, Inc. (&#8220;Oculus&#8221; or &#8220;Former Parent&#8221;) on March 26, 2014.</div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>
CY2013Q2 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
0 shares
CY2014Q2 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
3882105 shares
CY2013Q2 us-gaap Net Income Loss
NetIncomeLoss
-477000 USD
CY2014Q2 us-gaap Net Income Loss
NetIncomeLoss
-1715000 USD
CY2014Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-5384000 USD
CY2014Q1 us-gaap Prepaid Insurance
PrepaidInsurance
0 USD
CY2014Q2 us-gaap Prepaid Insurance
PrepaidInsurance
304000 USD
CY2014Q1 us-gaap Other Assets Current
OtherAssetsCurrent
1000 USD
CY2014Q2 us-gaap Other Assets Current
OtherAssetsCurrent
50000 USD
CY2014Q1 us-gaap Prepaid Rent
PrepaidRent
2000 USD
CY2014Q2 us-gaap Prepaid Rent
PrepaidRent
2000 USD
CY2014Q1 us-gaap Prepaid Expense And Other Assets
PrepaidExpenseAndOtherAssets
3000 USD
CY2014Q2 us-gaap Prepaid Expense And Other Assets
PrepaidExpenseAndOtherAssets
377000 USD
CY2014Q1 us-gaap Accrued Employee Benefits Current
AccruedEmployeeBenefitsCurrent
109000 USD
CY2014Q2 us-gaap Accrued Employee Benefits Current
AccruedEmployeeBenefitsCurrent
36000 USD
CY2014Q1 us-gaap Accounts Payable And Other Accrued Liabilities Current
AccountsPayableAndOtherAccruedLiabilitiesCurrent
15000 USD
CY2014Q2 us-gaap Accounts Payable And Other Accrued Liabilities Current
AccountsPayableAndOtherAccruedLiabilitiesCurrent
125000 USD
CY2014Q1 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
410000 USD
CY2014Q2 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
543000 USD
CY2014Q1 rtgn Accrued Director Compensation
AccruedDirectorCompensation
50000 USD
CY2014Q2 rtgn Accrued Director Compensation
AccruedDirectorCompensation
23000 USD
CY2014Q1 rtgn Accrued Legal Fees
AccruedLegalFees
183000 USD
CY2014Q2 rtgn Accrued Legal Fees
AccruedLegalFees
235000 USD
CY2014Q1 us-gaap Cash
Cash
15571000 USD
CY2014Q2 us-gaap Cash
Cash
14267000 USD
CY2014Q1 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
3000 USD
CY2014Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
377000 USD
CY2014Q1 us-gaap Assets Current
AssetsCurrent
15574000 USD
CY2014Q2 us-gaap Assets Current
AssetsCurrent
14644000 USD
CY2014Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
2000 USD
CY2014Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
3000 USD
CY2014Q1 us-gaap Assets
Assets
15576000 USD
CY2014Q2 us-gaap Assets
Assets
14647000 USD
CY2014Q1 us-gaap Due To Related Parties Current
DueToRelatedPartiesCurrent
537000 USD
CY2014Q2 us-gaap Due To Related Parties Current
DueToRelatedPartiesCurrent
7000 USD
CY2014Q1 us-gaap Liabilities Current
LiabilitiesCurrent
947000 USD
CY2014Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
4804290 shares
CY2013Q2 us-gaap Revenues
Revenues
0 USD
CY2014Q2 us-gaap Revenues
Revenues
0 USD
CY2013Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
175000 USD
CY2014Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
676000 USD
CY2013Q2 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
302000 USD
CY2014Q1 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2014Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2014Q1 us-gaap Preferred Stock Value
PreferredStockValue
0 USD
CY2014Q2 us-gaap Preferred Stock Value
PreferredStockValue
0 USD
CY2014Q1 us-gaap Common Stock Value
CommonStockValue
465 USD
CY2014Q2 us-gaap Common Stock Value
CommonStockValue
480 USD
CY2014Q1 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
18297535 USD
CY2014Q2 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
19480520 USD
CY2014Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-3669000 USD
CY2014Q1 us-gaap Stockholders Equity
StockholdersEquity
14629000 USD
CY2014Q2 us-gaap Stockholders Equity
StockholdersEquity
14097000 USD
CY2014Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
15576000 USD
CY2014Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
14647000 USD
CY2014Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2014Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2014Q1 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2014Q2 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2014Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
500000 shares
CY2014Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
500000 shares
CY2014Q1 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2014Q2 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2014Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2014Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2014Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000 shares
CY2014Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000 shares
CY2014Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
4650000 shares
CY2014Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
4804290 shares
CY2014Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
4650000 shares
CY2014Q2 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
1043000 USD
CY2013Q2 us-gaap Operating Expenses
OperatingExpenses
477000 USD
CY2014Q2 us-gaap Operating Expenses
OperatingExpenses
1719000 USD
CY2013Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-477000 USD
CY2014Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-1719000 USD
CY2013Q2 us-gaap Investment Income Nonoperating
InvestmentIncomeNonoperating
0 USD
CY2014Q2 us-gaap Investment Income Nonoperating
InvestmentIncomeNonoperating
4000 USD
CY2013Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
0 USD
CY2014Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
4000 USD
CY2013Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.24
CY2014Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.36
CY2013Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
2000000 shares
CY2014Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
4751730 shares
CY2013Q2 us-gaap Depreciation
Depreciation
1000 USD
CY2014Q2 us-gaap Depreciation
Depreciation
0 USD
CY2013Q2 us-gaap Share Based Compensation
ShareBasedCompensation
0 USD
CY2014Q2 us-gaap Share Based Compensation
ShareBasedCompensation
155000 USD
CY2013Q2 us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
99000 USD
CY2014Q2 us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
374000 USD
CY2013Q2 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
246000 USD
CY2014Q2 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
296000 USD
CY2013Q2 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-329000 USD
CY2014Q2 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-1638000 USD
CY2013Q2 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
0 USD
CY2014Q2 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
1000 USD
CY2013Q2 us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
0 USD
CY2014Q2 us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-1000 USD
CY2013Q2 us-gaap Proceeds From Related Party Debt
ProceedsFromRelatedPartyDebt
553000 USD
CY2014Q2 us-gaap Proceeds From Related Party Debt
ProceedsFromRelatedPartyDebt
0 USD
CY2013Q2 us-gaap Repayments Of Related Party Debt
RepaymentsOfRelatedPartyDebt
0 USD
CY2014Q2 us-gaap Repayments Of Related Party Debt
RepaymentsOfRelatedPartyDebt
530000 USD
CY2013Q2 us-gaap Payments Of Financing Costs
PaymentsOfFinancingCosts
509000 USD
CY2014Q2 us-gaap Payments Of Financing Costs
PaymentsOfFinancingCosts
0 USD
CY2013Q2 us-gaap Proceeds From Issuance Or Sale Of Equity
ProceedsFromIssuanceOrSaleOfEquity
0 USD
CY2014Q2 us-gaap Proceeds From Issuance Or Sale Of Equity
ProceedsFromIssuanceOrSaleOfEquity
865000 USD
CY2013Q2 rtgn Investment From Related Party
InvestmentFromRelatedParty
242000 USD
CY2014Q2 rtgn Investment From Related Party
InvestmentFromRelatedParty
0 USD
CY2013Q2 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
286000 USD
CY2014Q2 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
335000 USD
CY2013Q2 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-43000 USD
CY2014Q2 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-1304000 USD
CY2013Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
96000 USD
CY2014Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
15571000 USD
CY2013Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
53000 USD
CY2014Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
14267000 USD
CY2014Q2 us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
1028000 USD
CY2014Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
155000 USD
CY2014Q2 rtgn Gross Proceeds From Issuance Of Common Stock And Warrants
GrossProceedsFromIssuanceOfCommonStockAndWarrants
1117000 USD
CY2014Q2 rtgn Offering Cost
OfferingCost
252000 USD
CY2014Q2 rtgn Offering Cost Withheld From Proceeds
OfferingCostWithheldFromProceeds
89000 USD
CY2014Q2 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
163000 USD
CY2014Q2 rtgn Working Capital
WorkingCapital
14094000 USD
CY2014Q1 rtgn Other Prepaid Expenses And Current Assets
OtherPrepaidExpensesAndCurrentAssets
0 USD
CY2014Q2 rtgn Other Prepaid Expenses And Current Assets
OtherPrepaidExpensesAndCurrentAssets
21000 USD
CY2014Q1 rtgn Professional Fees Accrued Current
ProfessionalFeesAccruedCurrent
53000 USD
CY2014Q2 rtgn Professional Fees Accrued Current
ProfessionalFeesAccruedCurrent
124000 USD
CY2013Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0 pure
CY2014Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0167 pure
CY2013Q2 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P0Y
CY2014Q2 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P5Y7M10D
CY2014Q2 rtgn Share Based Compensation Arrangement By Sharebased Payment Award Nonoption Equity Instruments Exercisable Weighted Average Remaining Contractual Term
ShareBasedCompensationArrangementBySharebasedPaymentAwardNonoptionEquityInstrumentsExercisableWeightedAverageRemainingContractualTerm
P1Y8M12D
CY2014Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber
3145650 shares
CY2014Q2 rtgn Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Excercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExcercisableNumber
3047500 shares
CY2013Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0 pure
CY2014Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.95 pure
CY2013Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0 pure
CY2014Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.00 pure
CY2014Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
0 shares
CY2014Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
6.37
CY2014Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
332500 shares
CY2014Q2 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
6.37
CY2014Q2 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
0 shares
CY2014Q2 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
0
CY2014Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
0 shares
CY2014Q2 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
0
CY2014Q2 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P9Y10M24D
CY2014Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
0 USD
CY2014Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
0 shares
CY2014Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
0
CY2014Q2 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P0Y
CY2014Q2 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
0 USD
CY2014Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
332500 shares
CY2014Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
0
CY2014Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
1028000 USD
CY2014Q2 rtgn Share Based Compensation Arrangement By Share Based Payment Award Forfeiture Rights
ShareBasedCompensationArrangementByShareBasedPaymentAwardForfeitureRights
0 pure
CY2014Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
4.79
CY2014Q2 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
1593000 USD
CY2013Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
0 USD
CY2014Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
66000 USD
CY2014Q2 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
1527000 USD
CY2014Q2 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P2Y10M24D
CY2014Q2 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
431000 USD
CY2014Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Rights
ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights
RSUs for 341,000 shares of common stock vest ratably over three years on a quarterly basis and had an aggregate grant date value of $2,148,000. RSUs for 68,355 shares had an aggregate grant date value of $431,000 and vest in equal installments based on achievement of the following: (1) enrollment of the first patient in the first pivotal clinical trial for RUT58-60 on or prior to May 11, 2017; (2) enrollment of the first patient in the second pivotal clinical trial for RUT58-60 on or prior to May 11, 2018; and (3) completion of the clinical study report containing the results of the second pivotal clinical trial for RUT58-60 on or prior to May 11, 2019.
CY2014Q2 dei Document Type
DocumentType
10-Q
CY2014Q2 dei Amendment Flag
AmendmentFlag
false
CY2014Q2 dei Document Period End Date
DocumentPeriodEndDate
2014-06-30
CY2014Q2 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2015
CY2014Q2 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2014Q2 dei Entity Registrant Name
EntityRegistrantName
Ruthigen, Inc.
CY2014Q2 dei Entity Central Index Key
EntityCentralIndexKey
0001574235
CY2014Q2 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--03-31
CY2014Q2 dei Entity Filer Category
EntityFilerCategory
Smaller Reporting Company
CY2014Q2 dei Trading Symbol
TradingSymbol
RTGN
CY2014Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
4804290 shares
CY2014Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
332500 shares
CY2014Q2 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
6.37

Files In Submission

Name View Source Status
0001144204-14-050327-index-headers.html Edgar Link pending
0001144204-14-050327-index.html Edgar Link pending
0001144204-14-050327.txt Edgar Link pending
0001144204-14-050327-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xls Edgar Link pending
Financial_Report.xlsx Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
rtgn-20140630.xml Edgar Link completed
rtgn-20140630.xsd Edgar Link pending
rtgn-20140630_cal.xml Edgar Link unprocessable
rtgn-20140630_def.xml Edgar Link unprocessable
rtgn-20140630_lab.xml Edgar Link unprocessable
rtgn-20140630_pre.xml Edgar Link unprocessable
Show.js Edgar Link pending
v384507_10-q.htm Edgar Link pending
v384507_ex31-1.htm Edgar Link pending
v384507_ex31-2.htm Edgar Link pending
v384507_ex32.htm Edgar Link pending